nach oben

Neurotherapeutics

Erschienen in:

01.04.2015 | Review

Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis

verfasst von: Sami J. Barmada

Erschienen in: Neurotherapeutics | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

The degeneration of motor neurons in amyotrophic lateral sclerosis (ALS) inevitably causes paralysis and death within a matter of years. Mounting genetic and functional evidence suggest that abnormalities in RNA processing and metabolism underlie motor neuron loss in sporadic and familial ALS. Abnormal localization and aggregation of essential RNA-binding proteins are fundamental pathological features of sporadic ALS, and mutations in genes encoding RNA processing enzymes cause familial disease. Also, expansion mutations occurring in the noncoding region of C9orf72—the most common cause of inherited ALS—result in nuclear RNA foci, underscoring the link between abnormal RNA metabolism and neurodegeneration in ALS. This review summarizes the current understanding of RNA dysfunction in ALS, and builds upon this knowledge base to identify converging mechanisms of neurodegeneration in ALS. Potential targets for therapy development are highlighted, with particular emphasis on early and conserved pathways that lead to motor neuron loss in ALS.

Nur mit Berechtigung zugänglich

Charcot JM, Joffory A. Deux cas d'atrophie musculaire progressive avec lesions de la substance grise et des faisceaux antero-lateraux de la moelle epiniere. Arch Physiol Neurol Pathol 1869;2:744-754.

Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.PubMedCrossRef

Turner B, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 2008;85:94-134.PubMedCrossRef

Gill A, Kidd J, Vieira F, Thompson K, Perrin S. No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. PLoS ONE 2009;4:e6489.PubMedCentralPubMedCrossRef

Deng H-X, Chen W, Hong S-T, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011;477:211-215.PubMedCentralPubMedCrossRef

Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-133.PubMedCrossRef

Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;351:602-611.PubMedCrossRef

Fecto F, Yan J, Vemula SP, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 2011;68:1440-1446.PubMedCrossRef

Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010;68:857-864.PubMedCentralPubMedCrossRef

10.

Kim HJ, Kim NC, Wang Y-D, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013;495:467-473.PubMedCentralPubMedCrossRef

11.

Fang Y-S, Tsai K-J, Chang Y-J, et al. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat Commun 2014;5:4824.PubMedCrossRef

12.

Bosco DA, Morfini G, Karabacak NM, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010;13:1396-1403.PubMedCentralPubMedCrossRef

13.

Tollervey JR, Curk T, Rogelj B, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci 2011;14:452-458.PubMedCentralPubMedCrossRef

14.

Polymenidou M, Lagier-Tourenne C, Hutt KR, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 2011;14:459-468.PubMedCentralPubMedCrossRef

15.

Vance C, Rogelj B, Hortobágyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009;323:1208-1211.PubMedCrossRef

16.

Kwiatkowski TJ, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323:1205-1208.PubMedCrossRef

17.

Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-268.PubMedCentralPubMedCrossRef

18.

Dejesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245-256.PubMedCentralPubMedCrossRef

19.

Johnson JO, Pioro EP, Boehringer A, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci 2014;17:664-666.PubMedCentralPubMedCrossRef

20.

Alami NH, Smith RB, Carrasco MA, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 2014;81:536-543.PubMedCentralPubMedCrossRef

21.

Julien JP, Côté F, Collard JF. Mice overexpressing the human neurofilament heavy gene as a model of ALS. Neurobiol Aging 1995;16:487-490.PubMedCrossRef

22.

Ligon LA, LaMonte BH, Wallace KE, et al. Mutant superoxide dismutase disrupts cytoplasmic dynein in motor neurons. Neuroreport 2005;16:533-536.PubMedCrossRef

23.

Wu C-H, Wu C-H, Fallini C, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012;488:499–503.PubMedCentralPubMedCrossRef

24.

Novarino G, Fenstermaker AG, Zaki MS, et al. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. Science 2014;343:506-511.PubMedCentralPubMedCrossRef

25.

Ravits J, Appel S, Baloh RH, et al. Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14(S1):5-18.PubMedCentralPubMedCrossRef

26.

Neumann M. Molecular neuropathology of TDP-43 proteinopathies. Int J Mol Sci 2009;10:232-246.PubMedCentralPubMedCrossRef

27.

Barmada SJ, Finkbeiner S. Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease-associated pathways. Rev Neurosci 2010;21:251-272.PubMedCrossRef

28.

King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res 2012;1462:61-80.PubMedCentralPubMedCrossRef

29.

Smith R, Rathod RJ, Rajkumar S, Kennedy D. Nervous translation, do you get the message? A review of mRNPs, mRNA-protein interactions and translational control within cells of the nervous system. Cell Mol Life Sci 2014;71:3917-3937.PubMedCrossRef

30.

Couthouis J, Hart MP, Erion R, et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet 2012;21:2899-2911.PubMedCentralPubMedCrossRef

31.

Couthouis J, Hart MP, Shorter J, et al. A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A 2011;108:20881-20890.PubMedCentralPubMedCrossRef

32.

Pulst SM, Nechiporuk A, Nechiporuk T, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996;14:269-276.PubMedCrossRef

33.

Lattante S, Millecamps S, Stevanin G, et al. Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders. Neurology 2014;83:990-995.PubMedCrossRef

34.

Elden AC, Kim H-J, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010;466:1069-1075.PubMedCentralPubMedCrossRef

35.

Lee T, Li YR, Ingre C, et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet 2011;20:1697-1700.PubMedCentralPubMedCrossRef

36.

Lagier-Tourenne C, Polymenidou M, Hutt KR, et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci 2012;15:1488-1497.PubMedCentralPubMedCrossRef

37.

Sephton CF, Cenik C, Kucukural A, et al. Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J Biol Chem 2011;286:1204-1215.PubMedCentralPubMedCrossRef

38.

Xiao S, Sanelli T, Dib S, et al. RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS. Mol Cell Neurosci 2011;47:167-180.PubMedCrossRef

39.

Voigt A, Herholz D, Fiesel FC, et al. TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS ONE 2010;5:e12247.PubMedCentralPubMedCrossRef

40.

Ihara R, Ihara R, Matsukawa K, et al. RNA binding mediates neurotoxicity in the transgenic Drosophila model of TDP-43 proteinopathy. Hum Mol Genet 2013;22:4474-4484.PubMedCrossRef

41.

Daigle JG, Daigle JG, Lanson NA, et al. RNA binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations. Hum Mol Genet 2012;22:1193-1205.PubMedCentralPubMedCrossRef

42.

Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 2001;276:36337-36343.PubMedCrossRef

43.

Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442:920-924.PubMedCrossRef

44.

Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442:916-919.PubMedCrossRef

45.

Schymick JC, Yang Y, Andersen PM, et al. Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. J Neurol Neurosurg Psychiatry 2006;78:754-756.CrossRef

46.

Cannon A, Fujioka S, Rutherford NJ, et al. Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosis. Neurology 2013;80:1771-1777.PubMedCentralPubMedCrossRef

47.

Arnold ES, Ling S-C, Huelga SC, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A 2013;110:E736-E745.PubMedCentralPubMedCrossRef

48.

Ayala YM, Pantano S, D'Ambrogio A, et al. Human, Drosophila, and C. elegans TDP43: Nucleic acid binding properties and splicing regulatory function. J Mol Biol 2005;348:575-588.PubMedCrossRef

49.

Ayala YM, De Conti L, Avendaño-Vázquez SE, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J 2010;30:277-288.PubMedCentralPubMedCrossRef

50.

Avendano-Vazquez SE, Dhir A, Bembich S, Buratti E, Proudfoot N, Baralle FE. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev 2012;26:1679-1684.PubMedCentralPubMedCrossRef

51.

Liu-Yesucevitz L, Lin AY, Ebata A, et al. ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor. J Neurosci 2014;34:4167-4174.PubMedCentralPubMedCrossRef

52.

Wang I-F, Wu L-S, Chang H-Y, Shen C-KJ. TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem 2008;105:797-806.PubMedCrossRef

53.

McDonald KK, Aulas A, Destroismaisons L, et al. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet 2011;20:1400-1410.PubMedCrossRef

54.

Dewey CM, Cenik B, Sephton CF, et al. TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol Cell Biol 2011;31:1098-1108.PubMedCentralPubMedCrossRef

55.

Colombrita C, Zennaro E, Fallini C, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem 2009;111:1051-1061.PubMedCrossRef

56.

Liu-Yesucevitz L, Bilgutay A, Zhang Y-J, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS ONE 2010;5:e13250.PubMedCentralPubMedCrossRef

57.

Sephton CF, Good SK, Atkin S, et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem 2010;285:6826-6834.PubMedCentralPubMedCrossRef

58.

Wu L-S, Cheng W-C, Hou S-C, Yan Y-T, Jiang S-T, Shen C-KJ. TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. Genesis 2010;48:56-62.PubMed

59.

Honda D, Ishigaki S, Iguchi Y, et al. The ALS/FTLD-related RNA-binding proteins TDP-43 and FUS have common downstream RNA targets in cortical neurons. FEBS Open Bio 2013;4:1-10.PubMedCentralPubMedCrossRef

60.

Hazelett DJ, Chang J-C, Lakeland DL, Morton DB. Comparison of parallel high-throughput RNA sequencing between knockout of TDP-43 and its overexpression reveals primarily nonreciprocal and nonoverlapping gene expression changes in the central nervous system of Drosophila. G3 (Bethesda) 2012;2:789-802.

61.

Dormann D, Rodde R, Edbauer D, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J 2010;29:2841-2857.PubMedCentralPubMedCrossRef

62.

Colombrita C, Onesto E, Megiorni F, et al. TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells. J Biol Chem 2012;287:15635-15647.PubMedCentralPubMedCrossRef

63.

Qiu H, Lee S, Shang Y, et al. ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J Clin Invest 2014;124:981-999.PubMedCentralPubMedCrossRef

64.

Schwartz JC, Ebmeier CC, Podell ER, Heimiller J, Taatjes DJ, Cech TR. FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2. Genes Dev 2012;26:2690-2695.PubMedCentralPubMedCrossRef

65.

Tibshirani M, Tradewell ML, Mattina KR, et al. Cytoplasmic sequestration of FUS/TLS associated with ALS alters histone marks through loss of nuclear protein arginine methyltransferase 1. Hum Mol Genet 2015;24:773-786.PubMedCrossRef

66.

Sareen D, O'Rourke JG, Meera P, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med 2013;5:208ra149-208ra149.

67.

Lagier-Tourenne C, Baughn M, Rigo F, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A 2013;110:E4530-E4539.PubMedCentralPubMedCrossRef

68.

Donnelly CJ, Zhang P-W, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013;80:415-428.PubMedCentralPubMedCrossRef

69.

Kwon I, Xiang S, Kato M, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 2014;345:1139-1145.PubMedCrossRef

70.

Suzuki N, Maroof AM, Merkle FT, et al. The mouse C9ORF72 ortholog is enriched in neurons known to degenerate in ALS and FTD. Nat Neurosci 2013;16:1725-1727.PubMedCentralPubMedCrossRef

71.

Farg MA, Sundaramoorthy V, Sultana JM, et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum Mol Genet 2014;23:3579-3595.PubMedCentralPubMedCrossRef

72.

Rabin SJ, Kim JMH, Baughn M, et al. Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology. Hum Mol Genet 2009;19:313-328.PubMedCentralPubMedCrossRef

73.

Zhang Z, Lotti F, Dittmar K, et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 2008;133:585-600.PubMedCentralPubMedCrossRef

74.

Hideyama T, Teramoto S, Hachiga K, Yamashita T, Kwak S. Co-occurrence of TDP-43 mislocalization with reduced activity of an RNA editing enzyme, ADAR2, in aged mouse motor neurons. PLoS ONE 2012;7:e43469.PubMedCentralPubMedCrossRef

75.

Yamashita T, Kwak S. The molecular link between inefficient GluA2 Q/R site-RNA editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients. Brain Res 2014;1584:28-38.PubMedCrossRef

76.

Saldi TK, Ash PE, Wilson G, et al. TDP-1, the Caenorhabditis elegans ortholog of TDP-43, limits the accumulation of double-stranded RNA. EMBO J 2014;33:2947-2966.PubMedCentralPubMedCrossRef

77.

Freibaum BD, Chitta RK, High AA, Taylor JP. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res 2010;9:1104-1120.PubMedCentralPubMedCrossRef

78.

Wong SK, Sato S, Lazinski DW. Substrate recognition by ADAR1 and ADAR2. RNA 2001;7:846-858.PubMedCentralPubMedCrossRef

79.

Gomes A, Nolasco S, Soares H. Non-coding RNAs: Multi-tasking molecules in the cell. Int J Mol Sci 2013;14:16010-16039.PubMedCentralPubMedCrossRef

80.

Gascon E, Gao F-B. The emerging roles of microRNAs in the pathogenesis of frontotemporal dementia–amyotrophic lateral sclerosis (FTD-ALS) spectrum disorders. J Neurogenet 2014;28:30-40.PubMedCentralPubMedCrossRef

81.

Gregory RI, Yan K-P, Amuthan G, et al. The microprocessor complex mediates the genesis of microRNAs. Nature 2004;432:235-240.PubMedCrossRef

82.

Ling S-C, Albuquerque CP, Han JS, et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A 2010;107:13318-13323.PubMedCentralPubMedCrossRef

83.

Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci U S A 2012;109:3347-3352.PubMedCentralPubMedCrossRef

84.

Freischmidt A, Müller K, Ludolph AC, Weishaupt JH. Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol Commun 2013;1:42.PubMedCentralPubMedCrossRef

85.

Haramati S, Chapnik E, Sztainberg Y, et al. miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci U S A 2010;107:13111-13116.PubMedCentralPubMedCrossRef

86.

Schaefer A, O'Carroll D, Tan CL, et al. Cerebellar neurodegeneration in the absence of microRNAs. J Exp Med 2007;204:1553-1558.PubMedCentralPubMedCrossRef

87.

Udan M, Baloh RH. Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion 2011;5:1-5.PubMedCentralPubMedCrossRef

88.

Chernova TA, Wilkinson KD, Chernoff YO. Physiological and environmental control of yeast prions. FEMS Microbiol Rev 2014;38:326-344.PubMedCentralPubMedCrossRef

89.

Gitler AD, Shorter J. RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion 2011;5:179-187.PubMedCentralPubMedCrossRef

90.

Anderson P, Kedersha N. Stress granules: The Tao of RNA triage. Trends Biochem Sci 2008;33:141-150.PubMedCrossRef

91.

Yasuda K, Zhang H, Loiselle D, Haystead T, Macara IG, Mili S. The RNA-binding protein Fus directs translation of localized mRNAs in APC-RNP granules. J Cell Biol 2013;203:737-746.PubMedCentralPubMedCrossRef

92.

Baron DM, Kaushansky LJ, Ward CL, et al. Amyotrophic lateral sclerosis-linked FUS/TLS alters stress granule assembly and dynamics. Mol Neurodegener 2013;8:30.PubMedCentralPubMedCrossRef

93.

Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. J Cell Biol 2013;201:361-372.PubMedCentralPubMedCrossRef

94.

Higashi S, Kabuta T, Nagai Y, Tsuchiya Y, Akiyama H, Wada K. TDP-43 associates with stalled ribosomes and contributes to cell survival during cellular stress. J Neurochem 2013;126:288-300.PubMedCrossRef

95.

Parker SJ, Meyerowitz J, James JL, et al. Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochem Int 2012;60:415-424.PubMedCrossRef

96.

Buchan JR, Kolaitis R-M, Taylor JP, Parker R. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. Cell 2013;153:1461-1474.PubMedCentralPubMedCrossRef

97.

Watts GDJ, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004;36:377-381.PubMedCrossRef

98.

Furukawa Y, Kaneko K, Watanabe S, Yamanaka K, Nukina N. A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem 2011;286:18664-18672.PubMedCentralPubMedCrossRef

99.

Kim H-J, Raphael AR, LaDow ES, et al. Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet 2014;46:152-160.PubMedCentralPubMedCrossRef

100.

Figley MD, Bieri G, Kolaitis RM, Taylor JP, Gitler AD. Profilin 1 associates with stress granules and ALS-linked mutations alter stress granule dynamics. J Neurosci 2014;34(24): 8083-8097.

101.

McGurk L, Lee VM, Trojanowksi JQ, Van Deerlin VM, Lee EB, Bonini NM. Poly-A binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72. J Neuropathol Exp Neurol 2014;73:837-845.PubMedCrossRef

102.

Bentmann E, Neumann M, Tahirovic S, Rodde R, Dormann D, Haass C. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43). J Biol Chem 2012;287:23079-23094.PubMedCentralPubMedCrossRef

103.

Igaz LM, Kwong LK, Xu Y, et al. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol 2008;173:182-194.PubMedCentralPubMedCrossRef

104.

Fujii R, Takumi T. TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines. J Cell Sci 2005;118:5755-5765.PubMedCrossRef

105.

Carvalho T, Almeida F, Calapez A, Lafarga M, Berciano MT, Carmo-Fonseca M. The spinal muscular atrophy disease gene product, SMN: A link between snRNP biogenesis and the Cajal (coiled) body. J Cell Biol 1999;147:715-728.PubMedCentralPubMedCrossRef

106.

Tsuiji H, Iguchi Y, Furuya A, et al. Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. EMBO Mol Med 2013;5:221-234.PubMedCentralPubMedCrossRef

107.

Yamazaki T, Chen S, Yu Y, et al. FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Rep 2012;2:799-806.PubMedCentralPubMedCrossRef

108.

Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155-165.PubMedCrossRef

109.

Shan X, Chiang P-M, Price DL, Wong PC. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci U S A 2010;107:16325-16330.PubMedCentralPubMedCrossRef

110.

Ishihara T, Ariizumi Y, Shiga A, et al. Decreased number of Gemini of coiled bodies and U12 snRNA level in amyotrophic lateral sclerosis. Hum Mol Genet 2013;22:4136-4147.PubMedCrossRef

111.

Lee S, Lee TA, Lee E, et al. Identification of a subnuclear body involved in sequence-specific cytokine RNA processing. Nat Commun 2015;6:5791.PubMedCrossRef

112.

Herman AM, Khandelwal PJ, Rebeck GW, Moussa CE-H. Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models. Exp Neurol 2012;235:297–305.PubMedCentralPubMedCrossRef

113.

Evans MC, Couch Y, Sibson N, Turner MR. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 2013;53:34-41.PubMedCrossRef

114.

Armakola M, Higgins MJ, Figley MD, et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat Genet 2012;44:1-10.CrossRef

115.

Schwartz JC, Wang X, Podell ER, Cech TR. RNA seeds higher-order assembly of FUS protein. Cell Rep 2013;5:918-925.PubMedCentralPubMedCrossRef

116.

Chi Y-H, Semmes OJ, Jeang K-T. A proteomic study of TAR-RNA binding protein (TRBP)-associated factors. Cell Biosci 2011;1:9.PubMedCentralPubMedCrossRef

117.

Li L-B, Bonini NM. Roles of trinucleotide-repeat RNA in neurological disease and degeneration. Trends Neurosci 2010;33:292-298.PubMedCrossRef

118.

Meola G, Cardani R. Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Biochim Biophys Acta 2014 May 29 [Epub ahead of print].

119.

Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 2015;507:195-200.CrossRef

120.

Reddy K, Schmidt MHM, Geist JM, et al. Processing of double-R-loops in (CAG)·(CTG) and C9orf72 (GGGGCC)·(GGCCCC) repeats causes instability. Nucleic Acids Res 2014;42:10473-10487.PubMedCentralPubMedCrossRef

121.

Cooper-Knock J, Walsh MJ, Higginbottom A, et al. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain 2014;137(Pt 7):2040-2051.PubMedCentralPubMedCrossRef

122.

Lee Y-B, Chen H-J, Peres JN, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep 2013;5:1178-1186.PubMedCentralPubMedCrossRef

123.

Su Z, Zhang Y, Gendron TF, et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron 2014;83:1043-1050.PubMedCrossRef

124.

Nonaka T, Masuda-Suzukake M, Arai T, et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep 2013;4:124-134.PubMedCrossRef

125.

Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009;64:783-790.PubMedCrossRef

126.

Guo W, Chen Y, Zhou X, et al. An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat Struct Mol Biol 2011;18:822-830.PubMedCentralPubMedCrossRef

127.

Zhu L, Xu M, Yang M, et al. An ALS-mutant TDP-43 neurotoxic peptide adopts an anti-parallel β-structure and induces TDP-43 redistribution. Hum Mol Genet 2014;23:6863-6877.PubMedCrossRef

128.

Deleault NR, Lucassen RW, Supattapone S. RNA molecules stimulate prion protein conversion. Nature 2003;425:717-720.PubMedCrossRef

129.

Mackenzie IRA, Neumann M. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. Brain Res 2012;1462:40-43.PubMedCrossRef

130.

Mori K, Weng S-M, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013;339:1335-1338.PubMedCrossRef

131.

Ash PEA, Bieniek KF, Gendron TF, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013;77:639-646.PubMedCentralPubMedCrossRef

132.

Zu T, Gibbens B, Doty NS, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A 2011;108:260-265.PubMedCentralPubMedCrossRef

133.

Zu T, Liu Y, Bañez-Coronel M, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A 2013;110:E4968-E4977.PubMedCentralPubMedCrossRef

134.

Todd PK, Oh SY, Krans A, et al. CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron 2013;78:440-455.PubMedCrossRef

135.

Kochetov AV, Palyanov A, Titov II, Grigorovich D, Sarai A, Kolchanov NA. AUG_hairpin: prediction of a downstream secondary structure influencing the recognition of a translation start site. BMC Bioinformatics 2007;8:318.PubMedCentralPubMedCrossRef

136.

Mizielinska S, Grönke S, Niccoli T, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 2014;345:1192-1194.PubMedCrossRef

137.

May S, Hornburg D, Schludi MH, et al. C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol 2014;128:485-503.PubMedCentralPubMedCrossRef

138.

Wen X, Tan W, Westergard T, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 2014;84:1213-1225.PubMedCrossRef

139.

Knobel KM, Davis WS, Jorgensen EM, Bastiani MJ. UNC-119 suppresses axon branching in C. elegans. Development 2001;128:4079-4092.PubMed

140.

Hart MP, Gitler AD. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. J Neurosci 2012;32:9133-9142.PubMedCentralPubMedCrossRef

141.

Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci 2010;30:639-649.PubMedCentralPubMedCrossRef

142.

Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol 2007;17:193-201.PubMedCrossRef

143.

Ward ME, Taubes A, Chen R, et al. Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. J Exp Med 2014;177:311.

144.

Zhou Y, Liu S, Liu G, Oztürk A, Hicks GG. ALS-associated FUS mutations result in compromised FUS alternative splicing and autoregulation. PLoS Genet 2013;9:e1003895.PubMedCentralPubMedCrossRef

145.

Barmada SJ, Serio A, Arjun A, et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat Chem Biol 2014;10:677-685.PubMedCentralPubMedCrossRef

146.

Janssens J, Wils H, Kleinberger G, et al. Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice. Mol Neurobiol 2013;48:22-35.PubMedCentralPubMedCrossRef

147.

Igaz LM, Kwong LK, Lee EB, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest 2011;121:726-738.PubMedCentralPubMedCrossRef

148.

Xu Y-F, Prudencio M, Hubbard JM, et al. The pathological phenotypes of human TDP-43 transgenic mouse models are independent of downregulation of mouse Tdp-43. PLoS ONE 2013;8:e69864.PubMedCentralPubMedCrossRef

149.

Banerjee R, Beal MF, Thomas B. Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci 2010;33:541-549.PubMedCentralPubMedCrossRef

150.

Tsvetkov AS, Miller J, Arrasate M, Wong JS, Pleiss MA, Finkbeiner S. A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proc Natl Acad Sci U S A 2010;107:16982-16987.PubMedCentralPubMedCrossRef

151.

Hetz C, Thielen P, Matus S, et al. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev 2009;23:2294-2306.PubMedCentralPubMedCrossRef

152.

Wang I-F, Guo B-S, Liu Y-C, et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci U S A 2012;109:15024-15029.PubMedCentralPubMedCrossRef

153.

Hara T, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nat Cell Biol 2006;441:885-889.

154.

Bose JK, Huang C-C, Shen C-KJ. Regulation of autophagy by neuropathological protein TDP-43. J Biol Chem 2011;286:44441-44448.PubMedCentralPubMedCrossRef

Titel: Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis
verfasst von: Sami J. Barmada
Publikationsdatum: 01.04.2015
Verlag: Springer US
Erschienen in: Neurotherapeutics / Ausgabe 2/2015
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI: https://doi.org/10.1007/s13311-015-0340-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Neurologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Enhanced Retinal Ganglion Cell Survival in Glaucoma by Hypoxic Postconditioning After Disease Onset

Erratum to: TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets

Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

Rescue of Methyl-CpG Binding Protein 2 Dysfunction-induced Defects in Newborn Neurons by Pentobarbital

Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?

A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Neurologie